Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 10 of 10 entries
Sorted by: Best Match Show Resources per page
Antiviral Activity of 4'-thioIDU and Thymidine Analogs against Orthopoxviruses.

Viruses

Prichard MN, Kern ER.
PMID: 21994716
Viruses. 2010 Sep;2(9):1968-83. doi: 10.3390/v2091968. Epub 2010 Sep 16.

The search for effective therapies for orthopoxvirus infections has identified diverse classes of molecules with antiviral activity. Pyrimidine analogs, such as 5-iodo-2'-deoxyuridine (idoxuridine, IDU) were among the first compounds identified with antiviral activity against a number of orthopoxviruses and...

Cite
Prichard MN, Kern ER. Antiviral Activity of 4'-thioIDU and Thymidine Analogs against Orthopoxviruses. Viruses. 2010;2(9):1968-83doi: 10.3390/v2091968.
Prichard, M. N., & Kern, E. R. (2010). Antiviral Activity of 4'-thioIDU and Thymidine Analogs against Orthopoxviruses. Viruses, 2(9), 1968-83. https://doi.org/10.3390/v2091968
Prichard, Mark N, and Kern, Earl R. "Antiviral Activity of 4'-thioIDU and Thymidine Analogs against Orthopoxviruses." Viruses vol. 2,9 (2010): 1968-83. doi: https://doi.org/10.3390/v2091968
Prichard MN, Kern ER. Antiviral Activity of 4'-thioIDU and Thymidine Analogs against Orthopoxviruses. Viruses. 2010 Sep;2(9):1968-83. doi: 10.3390/v2091968. Epub 2010 Sep 16. PMID: 21994716; PMCID: PMC3185742.
Copy Download .nbib Format: NLM
Reviewing Antiviral Research Against Viruses Causing Human Diseases - A Structure Guided Approach.

Current molecular pharmacology

Sikdar A, Gupta R, Boura E.
PMID: 34348638
Curr Mol Pharmacol. 2021 Aug 04; doi: 10.2174/1874467214666210804152836. Epub 2021 Aug 04.

The littlest of all the pathogens, viruses have continuously been the foremost strange microorganisms to consider. Viral Infections can cause extreme sicknesses as archived by the HIV/AIDS widespread or the later Ebola or Zika episodes. Apprehensive framework distortions are...

Cite
Sikdar A, Gupta R, Boura E. Reviewing Antiviral Research Against Viruses Causing Human Diseases - A Structure Guided Approach. Curr Mol Pharmacol. 2021;doi: 10.2174/1874467214666210804152836.
Sikdar, A., Gupta, R., & Boura, E. (2021). Reviewing Antiviral Research Against Viruses Causing Human Diseases - A Structure Guided Approach. Current molecular pharmacology, . https://doi.org/10.2174/1874467214666210804152836
Sikdar, Arunima, et al. "Reviewing Antiviral Research Against Viruses Causing Human Diseases - A Structure Guided Approach." Current molecular pharmacology vol. (2021). doi: https://doi.org/10.2174/1874467214666210804152836
Sikdar A, Gupta R, Boura E. Reviewing Antiviral Research Against Viruses Causing Human Diseases - A Structure Guided Approach. Curr Mol Pharmacol. 2021 Aug 04; doi: 10.2174/1874467214666210804152836. Epub 2021 Aug 04. PMID: 34348638.
Copy Download .nbib Format: NLM
Behaviours of antiviral Oseltamivir in different media: DFT and SQMFF calculations.

Journal of molecular modeling

Vakili M, Romano E, Darugar V, Brandán SA.
PMID: 34812947
J Mol Model. 2021 Nov 23;27(12):357. doi: 10.1007/s00894-021-04962-3.

The synthetic cyclohexenecarboxylate ester antiviral Oseltamivir (O) have been theoretically studied by B3LYP/6-311 +  + G** calculations to estimate its reactivity and behaviour in gas and aqueous media. The most stable structure obtained in above media is consistent with...

Cite
Vakili M, Romano E, Darugar V, et al. Behaviours of antiviral Oseltamivir in different media: DFT and SQMFF calculations. J Mol Model. 2021;27(12):357doi: 10.1007/s00894-021-04962-3.
Vakili, M., Romano, E., Darugar, V., & Brandán, S. A. (2021). Behaviours of antiviral Oseltamivir in different media: DFT and SQMFF calculations. Journal of molecular modeling, 27(12), 357. https://doi.org/10.1007/s00894-021-04962-3
Vakili, Mohammad, et al. "Behaviours of antiviral Oseltamivir in different media: DFT and SQMFF calculations." Journal of molecular modeling vol. 27,12 (2021): 357. doi: https://doi.org/10.1007/s00894-021-04962-3
Vakili M, Romano E, Darugar V, Brandán SA. Behaviours of antiviral Oseltamivir in different media: DFT and SQMFF calculations. J Mol Model. 2021 Nov 23;27(12):357. doi: 10.1007/s00894-021-04962-3. PMID: 34812947; PMCID: PMC8608578.
Copy Download .nbib Format: NLM
Ganciclovir ophthalmic gel 0.15% for the treatment of acute herpetic keratitis: background, effectiveness, tolerability, safety, and future applications.

Therapeutics and clinical risk management

Chou TY, Hong BY.
PMID: 25187721
Ther Clin Risk Manag. 2014 Aug 20;10:665-81. doi: 10.2147/TCRM.S58242. eCollection 2014.

Eye disease due to herpes simplex virus (HSV) is a leading cause of ocular morbidity and the number one infectious cause of unilateral corneal blindness in the developed parts of the globe. Recurrent keratitis can result in progressive corneal...

Cite
Chou TY, Hong BY. Ganciclovir ophthalmic gel 0.15% for the treatment of acute herpetic keratitis: background, effectiveness, tolerability, safety, and future applications. Ther Clin Risk Manag. 2014;10:665-81doi: 10.2147/TCRM.S58242.
Chou, T. Y., & Hong, B. Y. (2014). Ganciclovir ophthalmic gel 0.15% for the treatment of acute herpetic keratitis: background, effectiveness, tolerability, safety, and future applications. Therapeutics and clinical risk management, 10665-81. https://doi.org/10.2147/TCRM.S58242
Chou, Timothy Y, and Hong, Bennett Y. "Ganciclovir ophthalmic gel 0.15% for the treatment of acute herpetic keratitis: background, effectiveness, tolerability, safety, and future applications." Therapeutics and clinical risk management vol. 10 (2014): 665-81. doi: https://doi.org/10.2147/TCRM.S58242
Chou TY, Hong BY. Ganciclovir ophthalmic gel 0.15% for the treatment of acute herpetic keratitis: background, effectiveness, tolerability, safety, and future applications. Ther Clin Risk Manag. 2014 Aug 20;10:665-81. doi: 10.2147/TCRM.S58242. eCollection 2014. PMID: 25187721; PMCID: PMC4149409.
Copy Download .nbib Format: NLM
Assessment of Cidofovir for Treatment of Ocular Bovine Herpesvirus-1 Infection in Cattle Using an Ex-Vivo Model.

Viruses

Alling CR, Liu CC, Langohr IM, Haque M, Carter RT, Baker RE, Lewin AC.
PMID: 34696532
Viruses. 2021 Oct 18;13(10). doi: 10.3390/v13102102.

Bovine herpesvirus-1 (BoHV-1) infection contributes to keratoconjunctivitis, respiratory disease, and reproductive losses in cattle. The objective of this study was to determine the most appropriate ophthalmic antiviral agent for BoHV-1 inhibition using in-vitro culture and novel ex-vivo bovine corneal...

Cite
Alling CR, Liu CC, Langohr IM, et al. Assessment of Cidofovir for Treatment of Ocular Bovine Herpesvirus-1 Infection in Cattle Using an Ex-Vivo Model. Viruses. 2021;13(10)doi: 10.3390/v13102102.
Alling, C. R., Liu, C. C., Langohr, I. M., Haque, M., Carter, R. T., Baker, R. E., & Lewin, A. C. (2021). Assessment of Cidofovir for Treatment of Ocular Bovine Herpesvirus-1 Infection in Cattle Using an Ex-Vivo Model. Viruses, 13(10), . https://doi.org/10.3390/v13102102
Alling, Christopher R, et al. "Assessment of Cidofovir for Treatment of Ocular Bovine Herpesvirus-1 Infection in Cattle Using an Ex-Vivo Model." Viruses vol. 13,10 (2021). doi: https://doi.org/10.3390/v13102102
Alling CR, Liu CC, Langohr IM, Haque M, Carter RT, Baker RE, Lewin AC. Assessment of Cidofovir for Treatment of Ocular Bovine Herpesvirus-1 Infection in Cattle Using an Ex-Vivo Model. Viruses. 2021 Oct 18;13(10). doi: 10.3390/v13102102. PMID: 34696532; PMCID: PMC8540818.
Copy Download .nbib Format: NLM
A new glimpse on the active site of SARS-CoV-2 3CLpro, coupled with drug repurposing study.

Molecular diversity

Novak J, Potemkin VA.
PMID: 35001230
Mol Divers. 2022 Jan 10; doi: 10.1007/s11030-021-10355-8. Epub 2022 Jan 10.

Coronavirus disease 2019 (COVID-19) is caused by novel severe acute respiratory syndrome coronavirus (SARS-CoV-2). Its main protease, 3C-like protease (3CLpro), is an attractive target for drug design, due to its importance in virus replication. The analysis of the radial...

Cite
Novak J, Potemkin VA. A new glimpse on the active site of SARS-CoV-2 3CLpro, coupled with drug repurposing study. Mol Divers. 2022;doi: 10.1007/s11030-021-10355-8.
Novak, J., & Potemkin, V. A. (2022). A new glimpse on the active site of SARS-CoV-2 3CLpro, coupled with drug repurposing study. Molecular diversity, . https://doi.org/10.1007/s11030-021-10355-8
Novak, Jurica, and Potemkin, Vladimir A. "A new glimpse on the active site of SARS-CoV-2 3CLpro, coupled with drug repurposing study." Molecular diversity vol. (2022). doi: https://doi.org/10.1007/s11030-021-10355-8
Novak J, Potemkin VA. A new glimpse on the active site of SARS-CoV-2 3CLpro, coupled with drug repurposing study. Mol Divers. 2022 Jan 10; doi: 10.1007/s11030-021-10355-8. Epub 2022 Jan 10. PMID: 35001230.
Copy Download .nbib Format: NLM
Historical perspectives in the development of antiviral agents against poxviruses.

Viruses

De Clercq E.
PMID: 21994682
Viruses. 2010 Jun;2(6):1322-39. doi: 10.3390/v2061322. Epub 2010 Jun 14.

The poxvirus vaccinia virus (VV) served as the model virus for which the first antivirals, the thiosemicarbazones, were identified. This dates back to 1950; and, although there is at present no single antiviral drug specifically licensed for the chemotherapy...

Cite
De Clercq E. Historical perspectives in the development of antiviral agents against poxviruses. Viruses. 2010;2(6):1322-39doi: 10.3390/v2061322.
De Clercq, E. (2010). Historical perspectives in the development of antiviral agents against poxviruses. Viruses, 2(6), 1322-39. https://doi.org/10.3390/v2061322
De Clercq, Erik. "Historical perspectives in the development of antiviral agents against poxviruses." Viruses vol. 2,6 (2010): 1322-39. doi: https://doi.org/10.3390/v2061322
De Clercq E. Historical perspectives in the development of antiviral agents against poxviruses. Viruses. 2010 Jun;2(6):1322-39. doi: 10.3390/v2061322. Epub 2010 Jun 14. PMID: 21994682; PMCID: PMC3185982.
Copy Download .nbib Format: NLM
Topical antiviral agents for herpes simplex virus infections.

Drugs of today (Barcelona, Spain : 1998)

Hamuy R, Berman B.
PMID: 14743269
Drugs Today (Barc). 1998 Dec;34(12):1013-25. doi: 10.1358/dot.1998.34.12.487486.

Several antiviral agents against herpes simplex virus (HSV) infection have been clinically studied. Earlier therapies include gluteraldehyde, povidone-iodine, butylated hydroxytoluene and ether. Nucleoside analogs have been tested for efficacy in HSV. Although acyclovir and adenine arabinoside have shown minimal...

Cite
Hamuy R, Berman B. Topical antiviral agents for herpes simplex virus infections. Drugs Today (Barc). 1998;34(12):1013-25doi: 10.1358/dot.1998.34.12.487486.
Hamuy, R., & Berman, B. (1998). Topical antiviral agents for herpes simplex virus infections. Drugs of today (Barcelona, Spain : 1998), 34(12), 1013-25. https://doi.org/10.1358/dot.1998.34.12.487486
Hamuy, R, and Berman, B. "Topical antiviral agents for herpes simplex virus infections." Drugs of today (Barcelona, Spain : 1998) vol. 34,12 (1998): 1013-25. doi: https://doi.org/10.1358/dot.1998.34.12.487486
Hamuy R, Berman B. Topical antiviral agents for herpes simplex virus infections. Drugs Today (Barc). 1998 Dec;34(12):1013-25. doi: 10.1358/dot.1998.34.12.487486. PMID: 14743269.
Copy Download .nbib Format: NLM
Behaviours of antiviral Oseltamivir in different media: DFT and SQMFF calculations.

Journal of molecular modeling

Vakili M, Romano E, Darugar V, Brandán SA.
PMID: 34812947
J Mol Model. 2021 Nov 23;27(12):357. doi: 10.1007/s00894-021-04962-3.

The synthetic cyclohexenecarboxylate ester antiviral Oseltamivir (O) have been theoretically studied by B3LYP/6-311 +  + G** calculations to estimate its reactivity and behaviour in gas and aqueous media. The most stable structure obtained in above media is consistent with...

Cite
Vakili M, Romano E, Darugar V, et al. Behaviours of antiviral Oseltamivir in different media: DFT and SQMFF calculations. J Mol Model. 2021;27(12):357doi: 10.1007/s00894-021-04962-3.
Vakili, M., Romano, E., Darugar, V., & Brandán, S. A. (2021). Behaviours of antiviral Oseltamivir in different media: DFT and SQMFF calculations. Journal of molecular modeling, 27(12), 357. https://doi.org/10.1007/s00894-021-04962-3
Vakili, Mohammad, et al. "Behaviours of antiviral Oseltamivir in different media: DFT and SQMFF calculations." Journal of molecular modeling vol. 27,12 (2021): 357. doi: https://doi.org/10.1007/s00894-021-04962-3
Vakili M, Romano E, Darugar V, Brandán SA. Behaviours of antiviral Oseltamivir in different media: DFT and SQMFF calculations. J Mol Model. 2021 Nov 23;27(12):357. doi: 10.1007/s00894-021-04962-3. PMID: 34812947; PMCID: PMC8608578.
Copy Download .nbib Format: NLM
A new glimpse on the active site of SARS-CoV-2 3CLpro, coupled with drug repurposing study.

Molecular diversity

Novak J, Potemkin VA.
PMID: 35001230
Mol Divers. 2022 Jan 10; doi: 10.1007/s11030-021-10355-8. Epub 2022 Jan 10.

Coronavirus disease 2019 (COVID-19) is caused by novel severe acute respiratory syndrome coronavirus (SARS-CoV-2). Its main protease, 3C-like protease (3CLpro), is an attractive target for drug design, due to its importance in virus replication. The analysis of the radial...

Cite
Novak J, Potemkin VA. A new glimpse on the active site of SARS-CoV-2 3CLpro, coupled with drug repurposing study. Mol Divers. 2022;doi: 10.1007/s11030-021-10355-8.
Novak, J., & Potemkin, V. A. (2022). A new glimpse on the active site of SARS-CoV-2 3CLpro, coupled with drug repurposing study. Molecular diversity, . https://doi.org/10.1007/s11030-021-10355-8
Novak, Jurica, and Potemkin, Vladimir A. "A new glimpse on the active site of SARS-CoV-2 3CLpro, coupled with drug repurposing study." Molecular diversity vol. (2022). doi: https://doi.org/10.1007/s11030-021-10355-8
Novak J, Potemkin VA. A new glimpse on the active site of SARS-CoV-2 3CLpro, coupled with drug repurposing study. Mol Divers. 2022 Jan 10; doi: 10.1007/s11030-021-10355-8. Epub 2022 Jan 10. PMID: 35001230; PMCID: PMC8743077.
Copy Download .nbib Format: NLM
Showing 1 to 10 of 10 entries